Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial
City of Hope Medical Center
City of Hope Medical Center
Pfizer
Guangdong Provincial People's Hospital
Fudan University
Sichuan University
Sichuan University
University Hospital, Essen
University of Kentucky
Hoosier Cancer Research Network
Tang-Du Hospital
Shanghai Pulmonary Hospital, Shanghai, China
Zhejiang Cancer Hospital
Spectrum Pharmaceuticals, Inc
Abramson Cancer Center at Penn Medicine
H. Lee Moffitt Cancer Center and Research Institute
Ain Shams University
The First People's Hospital of Lianyungang
AHS Cancer Control Alberta
ChineseAMS
Genentech, Inc.
National Cancer Center, Korea
Pfizer